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R Liu, KY Lai, CCY Lau, SH Liu, KH Chan, CK Lin, KY Yuen 
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BACKGROUND: Experience from influenza pandemics suggested that convalescent plasma 
treatment given within 4 to 5 days of symptom onset might be beneficial. However, robust 
treatment data are lacking. 
 
METHODS: This was a multicentre prospective double-blind randomised controlled trial. 
Convalescent plasma from patients who recovered from the 2009 pandemic influenza 
[A(H1N1)pdm09] infection was fractionated to hyperimmune intravenous immunoglobulin (H-
IVIG) by CSL Biotherapies, Australia. Patients with severe A(H1N1)pdm09 infection on 
standard antiviral treatment requiring intensive care and ventilatory support were randomised to 
receive H-IVIG or normal IVIG manufactured before 2009 as control. Clinical outcome and 
adverse effects were compared. 
 
RESULTS: Between 2010 and 2011, 35 patients were randomised to receive H-IVIG (17 patients) 
or IVIG (18 patients). One defaulted patient was excluded from analysis. No adverse event 
related to treatment was reported. Baseline demographics and viral load before treatment were 
similar between the two groups. Serial respiratory viral load demonstrated that H-IVIG treatment 
was associated with significantly lower day 5 and 7 post-treatment viral load when compared to 
the control (P = 0.04 and P = 0.02, respectively). The initial serum cytokine level was 
significantly higher in the H-IVIG group but fell to similar level 3 days after treatment. Subgroup 
multivariate analysis of the 22 patients who received treatment within 5 days of symptom onset 
demonstrated that H-IVIG treatment was the only factor which independently reduced mortality 
(odds ratio = 0.14; 95% confidence interval, 0.02-0.92; P = 0.04). 
 
CONCLUSIONS: Treatment of severe A(H1N1)pdm09 infection with H-IVIG within 5 days of 
symptom onset was associated with a lower viral load and reduced mortality. 
 
Note: The full manuscript was published in Chest 2013;144:464-73. 
